DC-BPi-03

CAS No. 2758411-46-8

DC-BPi-03( —— )

Catalog No. M36511 CAS No. 2758411-46-8

DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 337 In Stock
5MG 491 In Stock
10MG 787 In Stock
25MG 1398 In Stock
50MG 1822 In Stock
100MG 2403 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    DC-BPi-03
  • Note
    Research use only, not for human use.
  • Brief Description
    DC-BPi-03 is a potent BPTF-BRD inhibitor, exhibiting an IC50 of 698.3 nM and a Kd of 2.81 μM.
  • Description
    DC-BPi-03 is a potent BPTF-BRD inhibitor with an IC50?of 698.3 nM and a Kd of 2.81 μM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Chromatin/Epigenetic
  • Target
    Epigenetic Reader Domain
  • Recptor
    Epigenetic Reader Domain
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2758411-46-8
  • Formula Weight
    302.35
  • Molecular Formula
    C14H14N4O2S
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 33.33 mg/mL (110.24 mM; Ultrasonic (<80°C)
  • SMILES
    O=S(=O)(C=1N=C(C=C(N1)C2=CC=C3NC=CC3=C2)NC)C
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tian Lu, et al. Discovery of High-Affinity Inhibitors of the BPTF Bromodomain. J Med Chem. 2021 Aug 26;64(16):12075-12088.?
molnova catalog
related products
  • PBRM1-BD2-IN-7

    PBRM1-BD2-IN-7, a selective and cell-active inhibitor targeting the polybromo-1 (PBRM1) bromodomain, demonstrates inhibitory efficacy against PBRM1-BD2 with an IC50 value of 0.29 μM.

  • SGC2085 HCl

    SGC2085 is a potent and selective coactivator associated arginine methyltransferase 1 (CARM1) Inhibitor with an IC50 of 50 nM and more than undred-fold selectivity over other PRMTs.

  • PNZ5

    PNZ5 is a potent and isoxazole-based pan-BET inhibitor, with high selectivity and potency similar to the well-established (+)-JQ1.